NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis
Helpful tools for you, your patients, and their caregivers
For Healthcare Providers
A Closer Look: Proposed Mechanism of Action for NUPLAZID
Watch this video for the proposed mechanism of action for NUPLAZID. The precise mechanism of action of NUPLAZID in the treatment of hallucinations and delusions associated with Parkinson's disease psychosis is unclear.
PDP Proposed Mechanism of Disease and Mechanism of Action for NUPLAZID
Watch this video to see more of how the proposed mechanism of action for NUPLAZID relates to what a patient with Parkinson's disease psychosis may experience. The precise mechanism of action of NUPLAZID in the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis is unclear.
For Long-Term Care Facilities
Long-Term Care Service Request Form
Download and complete the long-term care service request form if you need long-term care access services.
For Patients & Caregivers
Designed to give your patients and their caregivers more detailed information about NUPLAZID.
Patient Video: Michael and Renee
Renee shares her and her husband's experience with hallucinations and delusions.
Patient Video: John Cwik
John talks about living with Parkinson's disease psychosis and his experience with NUPLAZID.
IMPORTANT SAFETY INFORMATION and INDICATION
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
- NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.
- Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.
Warnings and Precautions: QT Interval Prolongation
NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics.
NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.
- Adverse Reactions: The common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).
Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.
Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.
Indication NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Dosage and Administration Recommended dose: 34 mg capsule taken orally once daily, without titration.
NUPLAZID is available as 34 mg capsules and 10 mg tablets.
Please read the full Prescribing Information, including Boxed WARNING.